These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 20941458)

  • 41. Intimatan (dermatan 4,6-O-disulfate) prevents rethrombosis after successful thrombolysis in the canine model of deep vessel wall injury.
    Hong TT; Van Gorp CL; Cardin AD; Lucchesi BR
    Thromb Res; 2006; 117(3):333-42. PubMed ID: 15893368
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Construction and functional evaluation of hirudin derivatives with low bleeding risk.
    Zhang C; Yu A; Yuan B; Dong C; Yu H; Wang L; Wu C
    Thromb Haemost; 2008 Feb; 99(2):324-30. PubMed ID: 18278181
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fondaparinux and enoxaparin in comparison to unfractionated heparin in preventing thrombus formation on mechanical heart valves in an ex vivo rabbit model.
    Schlitt A; Buerke M; Hauroeder B; Peetz D; Hundt F; Bickel C; Schaefer I; Meyer J; Rupprecht HJ
    Thromb Haemost; 2003 Aug; 90(2):245-51. PubMed ID: 12888871
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial.
    van Aart L; Eijkhout HW; Kamphuis JS; Dam M; Schattenkerk ME; Schouten TJ; Ploeger B; Strengers PF
    Thromb Res; 2006; 118(3):313-20. PubMed ID: 16182346
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons.
    Fontayne A; Meiring M; Lamprecht S; Roodt J; Demarsin E; Barbeaux P; Deckmyn H
    Thromb Haemost; 2008 Oct; 100(4):670-7. PubMed ID: 18841291
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
    Mehta SR; Granger CB; Eikelboom JW; Bassand JP; Wallentin L; Faxon DP; Peters RJ; Budaj A; Afzal R; Chrolavicius S; Fox KA; Yusuf S
    J Am Coll Cardiol; 2007 Oct; 50(18):1742-51. PubMed ID: 17964037
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aprotinin could promote arterial thrombosis in pigs: a prospective randomized, blind study.
    Samama CM; Mazoyer E; Bruneval P; Ciostek P; Bonnin P; Bonneau M; Roussi J; Bailliart O; Pignaud G; Viars P
    Thromb Haemost; 1994 May; 71(5):663-9. PubMed ID: 7522355
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of fondaparinux versus enoxaparin in the survival of a congested skin flap in a rabbit model.
    Chung TL; Holton LH; Silverman RP
    Ann Plast Surg; 2006 Mar; 56(3):312-5. PubMed ID: 16508364
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa.
    Petitou M; Duchaussoy P; Herbert JM; Duc G; El Hajji M; Branellec JF; Donat F; Necciari J; Cariou R; Bouthier J; Garrigou E
    Semin Thromb Hemost; 2002 Aug; 28(4):393-402. PubMed ID: 12244487
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fondaparinux for the treatment of superficial-vein thrombosis in the legs.
    Decousus H; Prandoni P; Mismetti P; Bauersachs RM; Boda Z; Brenner B; Laporte S; Matyas L; Middeldorp S; Sokurenko G; Leizorovicz A;
    N Engl J Med; 2010 Sep; 363(13):1222-32. PubMed ID: 20860504
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk.
    Joyner CD; Peters RJ; Afzal R; Chrolavicius S; Mehta SR; Fox KA; Granger CB; Franzosi MG; Flather M; Budaj A; Bassand JP; Yusuf S
    Am Heart J; 2009 Mar; 157(3):502-8. PubMed ID: 19249421
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Successful emergency reversal of phenprocoumon anticoagulation with prothrombin complex concentrate: a prospective clinical study.
    Lorenz R; Kienast J; Otto U; Kiehl M; Schreiter D; Haertel S; Barthels M
    Blood Coagul Fibrinolysis; 2007 Sep; 18(6):565-70. PubMed ID: 17762533
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fondaparinux - data on efficacy and safety in special situations.
    Nagler M; Haslauer M; Wuillemin WA
    Thromb Res; 2012 Apr; 129(4):407-17. PubMed ID: 22133273
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of the hematocrit in a rabbit model of arterial thrombosis and bleeding.
    Quaknine-Orlando B; Samama CM; Riou B; Bonnin P; Guillosson JJ; Beaumont JL; Coriat P
    Anesthesiology; 1999 May; 90(5):1454-61. PubMed ID: 10319795
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Comparison of the effects of ketorolac and aspirin on hemostasis in the rabbit].
    Samama CM; Daghfous M; Delaporte-Cerceau S; Nafziger J; Drouet L; Riou B; Coriat P
    Ann Fr Anesth Reanim; 1995; 14(5):393-8. PubMed ID: 8572405
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of pentasaccharide on a prethrombosis model based on a calibrated stasis by the increase in up-stream venous pressure.
    Pottier P; Planchon B; Truchaud F; Leftheriotis G; Herbert JM; Bressollette L; Passuti N
    Blood Coagul Fibrinolysis; 2003 Sep; 14(6):587-91. PubMed ID: 12960613
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of the drugs used to reverse direct oral anticoagulants: a systematic review and meta-analysis.
    da Luz LT; Marchand M; Nascimento B; Tien H; Nathens A; Shah P
    Transfusion; 2017 Jul; 57(7):1834-1846. PubMed ID: 28337750
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prothrombin complex concentrate (PCC) for the treatment of coagulopathy associated with massive bleeding.
    Grottke O; Rossaint R
    Wien Klin Wochenschr; 2010 Dec; 122 Suppl 5():S23-4. PubMed ID: 21598445
    [No Abstract]   [Full Text] [Related]  

  • 59. Antithrombotic activity of the novel oral anticoagulant, Tecarfarin [Sodium 3-[4-((1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yloxy) carbonyl) benzyl]-2-oxo-2H-chromen-4-olate] in animal models.
    Bowersox SS; Canafax D; Druzgala P; Milner P; Weitz JI
    Thromb Res; 2010 Nov; 126(5):e383-8. PubMed ID: 20869102
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The synthetic pentasaccharide fondaparinux reduces coagulation, inflammation and neutrophil accumulation in kidney ischemia-reperfusion injury.
    Frank RD; Schabbauer G; Holscher T; Sato Y; Tencati M; Pawlinski R; Mackman N
    J Thromb Haemost; 2005 Mar; 3(3):531-40. PubMed ID: 15748244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.